Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U3-1402 in metastatic or unresectable non-small cell lung cancer
NL-OMON60232Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Primary endpoint(s). Started May 2020; status: completed.
02
Drugs
patritumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60232.